Key facts
- This page summarizes George Eric Davis's Form 4 filing for BIOMARIN PHARMACEUTICAL INC (BMRN).
- 4 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 06 May 2024, 16:45.
George Eric Davis - 02 May 2024 Form 4 Insider Report for BIOMARIN PHARMACEUTICAL INC (BMRN)
- Reporting relationship
- EVP, Chief Legal Officer
- Issuer ticker
- BMRN
- Reported as of
- 02 May 2024
- Net transaction value
- -$19,871
- SEC form
- 4
- Accepted by SEC
- 06 May 2024, 16:45:20 UTC
- Prior SEC filing
- 01 Apr 2024
- Next SEC filing
- 30 May 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Tae Sang Yoo, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
George Eric Davis filed Form 4 for BIOMARIN PHARMACEUTICAL INC (BMRN) on 06 May 2024.
Change
- Previous filing in this sequence was filed on 01 Apr 2024.
- Current net transaction value: -$19,871.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
BMRN
transaction
Common Stock
Award
- Transaction value
- $20,662
- Shares
- +301
- Change %
- +0.54%
- Price
- $68.65
- Shares after
- 56,157
- Date
- 30 Apr 2024
- Ownership
- Direct
- Footnotes
- F1
BMRN
transaction
Common Stock
Options Exercise
- Transaction value
- $116,735
- Shares
- +1,850
- Change %
- +3.3%
- Price
- $63.10
- Shares after
- 58,007
- Date
- 02 May 2024
- Ownership
- Direct
- Footnotes
- F2
BMRN
transaction
Common Stock
Sale
- Transaction value
- $157,268
- Shares
- -1,850
- Change %
- -3.2%
- Price
- $85.01
- Shares after
- 56,157
- Date
- 02 May 2024
- Ownership
- Direct
- Footnotes
- F2, F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
BMRN
transaction
Derivative
Stock Option (Right to Buy Common Stock)
Options Exercise
- Transaction value
- $0
- Shares
- -1,850
- Change %
- -4.3%
- Price
- $0.000000
- Shares after
- 40,850
- Date
- 02 May 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,850
- Exercise price
- $63.10
- Footnotes
- F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 4 footnotes
Footnote F1
Represents the shares acquired by the reporting person on April 30, 2024, pursuant to the issuer's Employee Stock Purchase Plan.
Footnote F2
Trade made pursuant to a 10b5-1 plan executed on September 13, 2023.
Footnote F3
The price in column 4 is the weighted average price. The purchase price actually received ranged from $85.00 to $85.03. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.
Footnote F4
Reflects the number of options outstanding after the transactions from this specific stock option grant.